




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

available at [www.sciencedirect.com](http://www.sciencedirect.com)  
journal homepage: [www.europeanurology.com](http://www.europeanurology.com)



## Letter to the Editor

**Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–293**

We read with interest the paper by Welén et al [1]. In the first section, the authors report on the time to discharge from hospital for men and women older than 50 yr with a positive SARS-CoV-2 polymerase chain reaction (PCR) test randomized to an enzalutamide group or a control group (hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.20–0.93). The authors found no effect of 4-d enzalutamide treatment on virus replication ( $p = 0.084$ ) in an in vitro primary lung model of human bronchial epithelial cells (HBECs). Enzalutamide treatment did not decrease the mRNA expression of *TMPRSS2* or *ACE2*. The authors also found no preventive effect of androgen inhibition therapy, while the combination of androgen deprivation therapy (ADT) and abiraterone acetate or enzalutamide increased the risk of dying from COVID-19 (HR 2.51, 95% CI 1.52–4.16). They have provided valuable insights into the effects of androgen inhibition in COVID-19. However, some points are worthy of further discussion.

In the second part of the study, HBECs were used to investigate the effect of enzalutamide treatment on mRNA expressions of *TMPRSS2* and *ACE2*, but evidence for androgen receptor (AR) expression in human lung cells is currently lacking [2]. Therefore, the lack of a decrease in *TMPRSS2* and *ACE2* mRNA expression levels is possibly due to the absence of a target for enzalutamide in HBECs. In previous studies, effects of enzalutamide on *TMPRSS2* and *ACE2* mRNA expression levels were mostly observed in murine animal models. Enzalutamide may possibly act on ARs in prostate cells and affect various downstream cytokine activities, thereby eventually changing the microenvironment surrounding lung cells [3]. Therefore, we would recommend that the authors use a co-culture system of prostate normal (or cancer) cells and HBECs and further analyze the changes in the downstream cytokines in their blood samples to clarify their study outcomes.

We would also recommend that the authors use a positive control with another antiandrogen therapy (eg, ARN-509 or abiraterone) to validate the results presented for the second part of the study. In addition, none of the three trials specified the SARS-CoV-2 strain(s) used, which might have affected the study outcomes. We suggest that the

authors should perform a subgroup analysis by SARS-CoV-2 strain. We also note that Table 2 [1] lists very different grade 3 adverse events between the enzalutamide and control groups, even though all events were labeled as not related or unlikely to be related to enzalutamide. We would recommend that the authors explain the possible underlying reasons for the differences in grade 3 adverse events observed in the two groups. Finally, we suggest that the authors should perform a multivariable analysis for Table 1 to investigate the effects of potential confounding variables, such as medications used in treatments and ventilator usage, on primary and secondary outcomes.

In conclusion, we are convinced that a co-culture system, analysis of cytokine levels in blood, and a positive control are all required to further validate the results presented for the second part of the study. Residual confounders and the differences in grade 3 adverse events also require some explanation.

**Conflicts of interest:** The authors have nothing to disclose.

## References

- [1] Welén K, Rosendal E, Gisslén M, et al. A phase 2 trial of the effect of antiandrogen therapy on COVID-19 Outcome: no evidence of benefit, supported by epidemiology and in vitro data. Eur Urol. In press. <https://doi.org/10.1016/j.eururo.2021.12.013>.
- [2] Mehrad M, Trejo Bittar HE, Yousem SA. Sex steroid receptor expression in idiopathic pulmonary fibrosis. Hum Pathol 2017;66:200–5. <https://doi.org/10.1016/j.humpath.2017.02.012>.
- [3] Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol 2015;67:470–9. <https://doi.org/10.1016/j.eururo.2014.09.049>.

Chen Dong<sup>a</sup>  
Sung-Lang Chen<sup>a,b</sup>  
Wen-Wei Sung<sup>a,b,c,\*</sup>

<sup>a</sup>School of Medicine, Chung Shan Medical University, Taichung, Taiwan  
<sup>b</sup>Department of Urology, Chung Shan Medical University Hospital, Taichung, Taiwan

<sup>c</sup>Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan

\*Corresponding author. Department of Urology, Chung Shan Medical University Hospital, Taichung, 40201 Taiwan. Tel. +886 4 24739595. E-mail address: [flutewayne@gmail.com](mailto:flutewayne@gmail.com) (W.-W. Sung).

January 11, 2022

DOI of original article: <https://doi.org/10.1016/j.eururo.2022.02.001>

<https://doi.org/10.1016/j.eururo.2022.01.048>

0302-2838/© 2022 European Association of Urology Published by Elsevier. All rights reserved.

